Transpek Industry Limited
1,245.00
INR
-63.30
(-4.84%)
ISIN
INE687A01016
Return %
Stock
S&P 500
1Y
- -
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Bimal Vasantlal Mehta
- Full Time Employees
- 935
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- Lilleria 1038 Vadodara GU India 390021
- IPO Date
- Jul 13, 1993
- Website
- transpek.com
- Similar Companies
- Business
- Transpek Industry Limited manufactures and exports a diverse range of chlorinated chemicals, specializing in acid chlorides and alkyl chlorides with expertise in sulphur and chlorine chemistry; its core products include thionyl chloride, chloro acetyl chloride, sodium hydro sulphite, and other organic and inorganic chemicals used in polymers, pharmaceuticals, agrochemicals, speciality chemicals, dyes, flavours, fragrances, and high-end applications such as defence, firefighting clothing, electric vehicles, and aircraft manufacturing. The company, founded in 1965 and headquartered in Vadodara, Gujarat, India, operates a multi-purpose production facility at Ekalbara near Vadodara, enabling custom synthesis, toll manufacturing, sulphonation, acid chloride reactions, Friedel-Crafts, and esterification processes. It serves a global customer base with exports comprising approximately 88% of sales, primarily to the USA (around 75%), Germany, China, and South Korea. Transpek Industry maintains a strong position as Asia's largest producer of thionyl chloride and acid chlorides outside Europe, supported by a long-term supply contract with a major global chemical player extending to 2028, featuring take-or-pay clauses that provide revenue visibility. Recent developments include the introduction and commercialization of new molecules over the past two years, expected to ramp up volumes in FY2025 following product approval cycles, alongside capacity expansion for a key molecule and diversification into Japan, South America, and Eurasia. The company incorporated a wholly owned subsidiary, Transpek Creative Chemistry Private Limited, in January 2020, and has initiated implementation of data analytics, machine learning, and AI models in FY2025 to enhance operational efficiency; it fully consolidates this subsidiary in its financials. In FY2024, despite macroeconomic headwinds causing a 30% revenue decline to Rs 586.7 crore, ICRA reaffirmed its [ICRA]A+ (Stable) ratings, citing a healthy financial risk profile with low gearing of 0.3x, comfortable coverage ratios, and projected cash accruals of Rs 75-90 crore annually amid modest capex plans.